胰岛素生长因子受体-2在肝细胞癌预后判断中的临床价值
| 作者: |
1丁晶晶,
2,3陈洁,
1刘欣艳
1 上海市普陀区中心医院老年科，上海 200062 2 湖北医药学院附属随州医院肿瘤科，湖北 随州 44130 3 南通大学医学院肿瘤学，江苏 南通 226001 |
| 通讯: |
刘欣艳
Email: xyan020699@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2017.06.026 |
摘要
目的：探讨胰岛素生长因子受体-2(insulin-like growth factor-2 receptor，IGF-2R)在肝细胞癌(hepatocellular carcinoma，HCC)预后判断中的临床价值。方法：采用免疫组织化学染色(IHC)检测人类肝癌组织中IGF-2R的表达，并分析IGF-2R组织水平与HCC患者临床病理特征之间关系。结果：IHC结果显示IGF-2R主要在HCC细胞的胞质和胞膜中表达，与匹配的癌旁正常组织相比，IGF-2R蛋白水平在HCC组织中更高，差异有统计学意义(P<0.05)，并且与肿瘤分化程度正相关(P=0.012)。单变量和多变量生存分析显示TNM分期(HR=9.87，95%CI 4.13~17.80，P=0.008)、门脉癌栓(HR=5.21，95%CI 1.38~10.76，P=0.023)和IGF-2R高表达(HR=2.30，95%CI 1.20~5.01，P=0.033)与HCC患者预后不良相关。结论：这些数据表明IGF-2R表达与HCC患者的总体存活负相关，是潜在的HCC新型分子靶标和预后标志物。
关键词：
肝细胞癌
胰岛素生长因子受体-2
预后
存活
分子靶向
Clinical value of IGF-2R in prognosis of hepatocellular carcinoma
CorrespondingAuthor: LIU Xinyan Email: xyan020699@163.com
DOI: 10.3978/j.issn.2095-6959.2017.06.026
Abstract
Objective: To study the clinical value of insulin-like growth factor-2 receptor (IGF-2R) in the prognosis of hepatocellular carcinoma (HCC). Methods: We examined IGF-2R expression in human HCC tissues by immunohistochemical staining, and investigated the clinical correlation between IGF-2R tissue levels and the clinicopathological characteristics of HCC patients. Results: Immunohistochemistry results revealed that IGF-2R was mainly expressed in the cell membrane and plasma of HCC cells. IGF-2R protein levels were significantly higher in HCC tissues when compared with matched non-cancerous tissues, the difference was statistically significant (P<0.05), and associated with the degree of tumor differentiation (P=0.012). Univariate and multivariate survival analysis revealed that patients with high IGF-2R expression (HR =9.87, 95% CI 4.13–17.80, P=0.008) and advanced TNM stage (HR =5.21, 95% CI 1.38–10.76, P=0.023) and poor prognosis (HR =2.30, 95% CI 1.20–5.01, P=0.033). Conclusion: These data indicate that IGF-2R expression is associated with the overall survival of HCC patients, and may represent a novel molecular target and new prognostic biomarker for HCC.